Biofrontera AGBIFRF 58 Return-on-Tangible-Equity is 55.63% as of Mar. 2026. GuruFocus rates BIFRF with a GF Score™ of 58/100 and a GF Value™ of $31.34. The stock has 4 warning signs investors should review. Among 898 Drug Manufacturers companies, Biofrontera AG ranks worse than 83.07% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Biofrontera AG's annualized net income for the quarter that ended in Mar. 2026 was $10.17 Mil. Biofrontera AG's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $18.29 Mil. Therefore, Biofrontera AG's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 55.63%.
The historical rank and industry rank for Biofrontera AG's Return-on-Tangible-Equity or its related term are showing as below:
BIFRF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -473.18 Med: -94.76 Max: 164.22
Current: -15.27
During the past 13 years, Biofrontera AG's highest Return-on-Tangible-Equity was 164.22%. The lowest was -473.18%. And the median was -94.76%.
BIFRF's Return-on-Tangible-Equity is ranked worse than 83.07% of 898
companies
in the Drug Manufacturers industry
Industry Median: 7.88
vs BIFRF: -15.27
Biofrontera AG (OTCPK:BIFRF) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Biofrontera AG Return-on-Tangible-Equity Related Terms
Biofrontera AG Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Biofrontera AG's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BIFRF vs ZTS, UTHR, VTRS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera AG's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biofrontera AG Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biofrontera AG's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Biofrontera AG's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 55.63% mean?
Biofrontera AG (BIFRF) has a Return-on-Tangible-Equity of 55.63% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Biofrontera AG and its competitors. According to the industry distribution chart, Biofrontera AG ranks #746 out of 898 companies in the Drug Manufacturers industry, placing it in the top 83.1%.
Is Biofrontera AG's Return-on-Tangible-Equity too high?
Biofrontera AG's current Return-on-Tangible-Equity is 55.63%. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.88. Biofrontera AG's value of 55.63% is 606% above this industry median. Based on the distribution chart, Biofrontera AG ranks #746 out of 898 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Biofrontera AG has a GF Score™ of 58/100, reflecting its overall financial health beyond just this single metric.
How does Biofrontera AG's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Biofrontera AG ranks #746 out of 898 companies for Return-on-Tangible-Equity. This places Biofrontera AG in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.88. Biofrontera AG's value of 55.63% is 606% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.88, based on 898 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biofrontera AG's current Return-on-Tangible-Equity of 55.63% is 606% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Biofrontera AG and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biofrontera AG's current Return-on-Tangible-Equity is 55.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofrontera AG stock overvalued right now?
Biofrontera AG (BIFRF) has a current Return-on-Tangible-Equity of 55.63%. The stock's GF Value™ is $31.34, compared to a current price of $22.68 — trading 27.6% below its estimated fair value. The current Return-on-Tangible-Equity is 55.63% and 606% above the Drug Manufacturers industry median of 7.88. Biofrontera AG's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Biofrontera AG (BIFRF), the current Return-on-Tangible-Equity is 55.63% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biofrontera AG (BIFRF) Overvalued in 2026?
Based on GuruFocus' analysis, Biofrontera AG stock appears to be undervalued.
The current stock price of $22.68 is trading 27.6% below its estimated GF Value™ of $31.34.
Key valuation signals for BIFRF:
Return-on-Tangible-Equity: 55.63%
GF Value™: $31.34 vs. price of $22.68 (27.6% below fair value)
Industry Position: 606% above the Drug Manufacturers median (#746 of 898)
No single metric tells the full story. See the BIFRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED and BF-RhodoLED XL, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin. Geographically, the company generates maximum revenue from Germany, and the rest from Spain, the United Kingdom, the rest of Europe, and other regions.
58GF Score
Get the complete analysis for BIFRF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIFRF has been successfully added to your 
